Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAP3K11 | Q16584 | 5/20 | 0.53 |
| ▸ | FLT3 | P36888 | 4/20 | 0.53 |
| ▸ | CDK2 | P24941 | 3/20 | 0.53 |
| ▸ | IKBKB | O14920 | 3/20 | 0.53 |
| ▸ | CHUK | O15111 | 3/20 | 0.53 |
| ▸ | ABL1 | P00519 | 2/20 | 0.53 |
| ▸ | INSR | P06213 | 2/20 | 0.53 |
| ▸ | CCNK | O75909 | 1/20 | 0.52 |
| ▸ | CDK4 | P11802 | 1/20 | 0.52 |
| ▸ | CCND1 | P24385 | 1/20 | 0.52 |
| ▸ | CCNA1 | P78396 | 1/20 | 0.52 |
| ▸ | CDK6 | Q00534 | 1/20 | 0.52 |
| ▸ | CDK13 | Q14004 | 1/20 | 0.52 |
| ▸ | CDK12 | Q9NYV4 | 1/20 | 0.52 |
| ▸ | PIM2 | Q9P1W9 | 1/20 | 0.52 |
| ▸ | JAK2 | O60674 | 4/20 | 0.51 |
| ▸ | TNIK | Q9UKE5 | 6/20 | 0.49 |
| ▸ | SGK1 | O00141 | 1/20 | 0.49 |
| ▸ | AURKA | O14965 | 1/20 | 0.49 |
| ▸ | PRKAB2 | O43741 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19823106 | 0.89 | JAK2 (0.55) | FLT3IKBKBCHUKABL1JAK2 | |
| SCHEMBL19823052 | 0.86 | JAK1 (0.49) | FLT3IKBKBCHUKABL1JAK2 | |
| SCHEMBL19823110 | 0.85 | CSF1R (0.55) | FLT3CDK2IKBKBCHUKABL1 | |
| SCHEMBL19823104 | 0.84 | JAK2 (0.50) | FLT3IKBKBCHUKABL1JAK2 | |
| SCHEMBL21078404 | 0.83 | IKBKB (0.49) | FLT3IKBKBCHUKABL1JAK2 | |
| SCHEMBL4790876 | 0.81 | MAP3K11 (0.56) | MAP3K11FLT3CDK2IKBKBCHUK | |
| SCHEMBL21044826 | 0.77 | JAK2 (0.60) | FLT3IKBKBCHUKABL1JAK2 | |
| SCHEMBL16793627 | 0.76 | JAK2 (0.66) | FLT3IKBKBCHUKABL1JAK2 | |
| SCHEMBL20752269 | 0.75 | JAK2 (0.60) | FLT3IKBKBCHUKABL1JAK2 | |
| SCHEMBL15154791 | 0.73 | MAP3K11 (0.80) | MAP3K11FLT3CDK2IKBKBCHUK |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11279699-B2 | Compound as selective JAK inhibitor, and salt and therapeutic use thereof | SUZHOU LONGBIOTECH PHARMACEUTICALS CO., LTD. (CN) | 2022-03-22 | — | — | US | claimed |
| US-20200190080-A1 | COMPOUND AS SELECTIVE JAK INHIBITOR, AND SALT AND THERAPEUTIC USE THEREOF | TIANJIN LONGBOGENE PHARMACEUTICAL CO., LTD. (CN) | 2020-06-18 | — | — | US | claimed |
| EP-3492469-A1 | COMPOUND AS SELECTIVE JAK INHIBITOR, AND SALT AND THERAPEUTIC USE THEREOF | Tianjin Longbogene Pharmaceutical Co., Ltd. (CN) | 2019-06-05 | — | — | EP | claimed |
| CN-109843883-A | Alternatively property JAK inhibitor compound, the salt and its therapeutical uses of the compound | 天津隆博基因药物科技有限公司 | 2019-06-04 | — | — | CN | claimed |
| US-11279699-B2 | Compound as selective JAK inhibitor, and salt and therapeutic use thereof | SUZHOU LONGBIOTECH PHARMACEUTICALS CO., LTD. (CN) | 2022-03-22 | — | — | US | disclosed |
| US-11279699-B2 | Compound as selective JAK inhibitor, and salt and therapeutic use thereof | SUZHOU LONGBIOTECH PHARMACEUTICALS CO., LTD. (CN) | 2022-03-22 | — | — | US | disclosed |
| EP-3492469-B1 | COMPOUND AS SELECTIVE JAK INHIBITOR, AND SALT AND THERAPEUTIC USE THEREOF | SUZHOU LONGBIOTECH PHARMACEUTICALS CO LTD (CN) | 2021-12-01 | — | — | EP | disclosed |
| EP-3492469-B1 | COMPOUND AS SELECTIVE JAK INHIBITOR, AND SALT AND THERAPEUTIC USE THEREOF | SUZHOU LONGBIOTECH PHARMACEUTICALS CO LTD (CN) | 2021-12-01 | — | — | EP | disclosed |
| US-20200190080-A1 | COMPOUND AS SELECTIVE JAK INHIBITOR, AND SALT AND THERAPEUTIC USE THEREOF | TIANJIN LONGBOGENE PHARMACEUTICAL CO., LTD. (CN) | 2020-06-18 | — | — | US | disclosed |
| US-20200190080-A1 | COMPOUND AS SELECTIVE JAK INHIBITOR, AND SALT AND THERAPEUTIC USE THEREOF | TIANJIN LONGBOGENE PHARMACEUTICAL CO., LTD. (CN) | 2020-06-18 | — | — | US | disclosed |
| EP-3492469-A1 | COMPOUND AS SELECTIVE JAK INHIBITOR, AND SALT AND THERAPEUTIC USE THEREOF | Tianjin Longbogene Pharmaceutical Co., Ltd. (CN) | 2019-06-05 | — | — | EP | disclosed |
| EP-3492469-A1 | COMPOUND AS SELECTIVE JAK INHIBITOR, AND SALT AND THERAPEUTIC USE THEREOF | Tianjin Longbogene Pharmaceutical Co., Ltd. (CN) | 2019-06-05 | — | — | EP | disclosed |
| CN-109843883-A | Alternatively property JAK inhibitor compound, the salt and its therapeutical uses of the compound | 天津隆博基因药物科技有限公司 | 2019-06-04 | — | — | CN | disclosed |
| WO-2018019223-A1 | COMPOUND AS SELECTIVE JAK INHIBITOR, AND SALT AND THERAPEUTIC USE THEREOF | 张文燕 | 2018-02-01 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200190080-A1 | COMPOUND AS SELECTIVE JAK INHIBITOR, AND SALT AND THERAPEUTIC USE THEREOF | JAK1, JAK2, JAK3 | MAP3K11 32/4885FLT3 241/4885CDK2 657/4885 |
| US-11279699-B2 | Compound as selective JAK inhibitor, and salt and therapeutic use thereof | JAK1, JAK2, JAK3 | MAP3K11 32/4885FLT3 241/4885CDK2 657/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.